Menu
Peptide Database
Results
No peptides found
Featured

Use search to browse all 100+ peptides

Melanotan-I

Afamelanotide, MT-I, [Nle4-D-Phe7]-α-MSH, Scenesse, CUV-1647

Quick Stats
Studies 225
Trials 100
Score 2
2000 pubmed

Hypothalamic localization of the feeding effect of agouti-related peptide and alpha-melanocyte-stimulating hormone.

Kim. M S MS; Rossi. M M; Abusnana. S S; Sunter. D D; Morgan. D G DG; Small. C J CJ; Edwards. C M CM; Heath. M M MM; Stanley. S A SA; Seal. L J LJ; Bhatti. J R JR; Smith. D M DM; Ghatei. M A MA; Bloom. S R SR

Key Findings

  • Injecting the MC4R antagonist AgRP into the PVN, DMN, or MPO boosted eating by 200‑300% in rats.
  • Injecting the stable MC4R agonist NDP‑MSH into the same regions cut food intake by about 45‑55% within an hour.
  • Other hypothalamic sites (Arc, LHA, VMN) showed little or no response to AgRP, and only modest suppression with NDP‑MSH.

Practical Outcomes

  • The main takeaway is that MC4R activation in specific hypothalamic nuclei can suppress appetite, supporting the theoretical use of melanotan‑I for appetite control. However, because the study used direct brain injections in rats, it doesn’t translate into a ready‑to‑use protocol for humans. More research is needed to determine safe, effective systemic dosing and delivery methods for self‑experimenters.

Summary

This rat study shows that activating the MC4R receptor in certain brain areas (especially the PVN, DMN, and MPO) cuts food intake, while blocking it makes rats eat a lot more. The effects were seen when the compounds were injected directly into the brain, not when taken orally or by injection elsewhere. So while it backs up the idea that MC4R‑activating peptides like melanotan‑I could curb appetite, the work doesn’t give a practical dosing guide for humans.

Abstract

The melanocortin-4 receptor (MC4R) in the hypothalamus is thought to be important in physiological regulation of food intake. We investigated which hypothalamic areas known to express MC4R are involved in the regulation of feeding by using alpha-melanocyte-stimulating hormone (alpha-MSH), an endogenous MC4R agonist, and agouti-related peptide (Agrp), an endogenous MC4R antagonist. Cannulae were inserted into the rat hypothalamic paraventricular (PVN), arcuate (Arc), dorsomedial (DMN), and ventromedial (VMN) nuclei; the medial preoptic (MPO), anterior hypothalamic (AHA), and lateral hypothalamic (LHA) areas; and the extrahypothalamic central nucleus of the amygdala (CeA). Agrp (83-132) (0.1 nmol) and [Nle4, D-Phe7]alpha(-MSH (NDP-MSH) (0.1 nmol), a stable alpha-MSH analog, were administered to fed and fasted rats, respectively. The PVN, DMN, and MPO were the areas with the greatest response to Agrp and NDP-MSH. At 8 h postinjection, Agrp increased feeding in the PVN by 218 +/- 23% (P < 0.005), in the DMN by 268 +/- 42% (P < 0.005), and in the MPO by 236 +/- 31% (P < 0.01) compared with a saline control group for each nucleus. NDP-MSH decreased food intake in the PVN by 52 +/- 6% (P < 0.005), in the DMN by 44 +/- 6% (P < 0.0001), and in the MPO by 55 +/- 6% (P < 0.0001) at 1 h postinjection. Injection into the AHA and CeA resulted in smaller alterations in food intake. No changes in feeding were seen after the administration of Agrp into the Arc, LHA, or VMN, but NDP-MSH suppressed food intake in the Arc and LHA. This study indicates that the hypothalamic nuclei expressing MC4R vary in their sensitivity to Agrp and alpha-MSH with regard to their effect on feeding.

Study Information

Provider

pubmed

Year

2000

DOI

10.2337/diabetes.49.2.177